TY - T1的回答:关于的建议the GINA strategy report on asthma step 1 JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.04226-2020 VL - 57 IS - 2 SP - 2004226 AU - Reddel, Helen K. Y1 - 2021/02/01 UR - //www.qdcxjkg.com/content/57/2/2004226.abstract N2 - The changes to treatment recommendations for mild asthma published by the Global Initiative for Asthma (GINA) in 2019 [1], and further updated in 2020 [2], have prompted extensive discussion. The letter by S. Ferretti and co-workers provides the opportunity to correct some misunderstandings, and to respond to questions about why as-needed short-acting β2-agonist (SABA) alone is no longer recommended in step 1 of the GINA treatment figure for adults and adolescents. The term “step 1” refers to a particular level of treatment and not to a type of patient or a phenotype of asthma.The recommendation by GINA against SABA-only treatment of asthma for adults and adolescents is supported by evidence of harm from even modest SABA over-use, and strong evidence for as-needed ICS–formoterol as a safe and effective way to reduce asthma risk https://bit.ly/3oy0tK2 ER -